PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
Fiche publication
Date publication
janvier 2016
Journal
Cancer cell international
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DANTZER Françoise, Dr SCHREIBER Valérie
Tous les auteurs :
Noll A, Illuzzi G, Amé JC, Dantzer F, Schreiber V
Lien Pubmed
Résumé
Poly(ADP-ribose) polymerase (PARP) inhibitors have entered the clinics for their promising anticancer effect as adjuvant in chemo- and radiotherapy and as single agent on BRCA-mutated tumours. Poly(ADP-ribose) glycohydrolase (PARG) deficiency was also shown to potentiate the cytotoxicity of genotoxic agents and irradiation. The aim of this study is to investigate the effect of PARG deficiency on BRCA1- and/or PTEN-deficient tumour cells.
Référence
Cancer Cell Int.. 2016 ;16:53